Key Points
- Pacira BioSciences SVP Lauren Riker sold 6,115 shares on June 11 at an average price of $23.50, worth about $143,702. The sale was made under a pre-arranged Rule 10b5-1 plan.
- After the transaction, Riker still owned 62,284 shares valued at about $1.46 million, representing an 8.94% reduction in her stake.
- Pacira recently reported quarterly revenue of $177.38 million, topping estimates, while EPS of $0.60 narrowly missed expectations. Analysts currently rate the stock a Hold on average, with a target price of $29.40.
Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) SVP Lauren Riker sold 6,115 shares of the firm's stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $23.50, for a total value of $143,702.50. Following the completion of the transaction, the senior vice president directly owned 62,284 shares of the company's stock, valued at $1,463,674. The trade was a 8.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Pacira BioSciences Price Performance
Pacira BioSciences stock opened at $22.99 on Friday. Pacira BioSciences, Inc. has a one year low of $18.80 and a one year high of $27.64. The business has a fifty day moving average price of $23.58 and a 200-day moving average price of $23.27. The company has a debt-to-equity ratio of 0.56, a current ratio of 4.73 and a quick ratio of 3.35. The firm has a market capitalization of $904.66 million, a P/E ratio of 191.60 and a beta of 0.29.
Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The company reported $0.60 EPS for the quarter, missing analysts' consensus estimates of $0.61 by ($0.01). Pacira BioSciences had a return on equity of 10.24% and a net margin of 0.70%.The company had revenue of $177.38 million during the quarter, compared to the consensus estimate of $171.80 million. During the same period in the previous year, the business earned $0.65 earnings per share. Pacira BioSciences's revenue was up 5.0% on a year-over-year basis. As a group, equities research analysts forecast that Pacira BioSciences, Inc. will post 1.91 EPS for the current year.
Institutional Investors Weigh In On Pacira BioSciences
A number of institutional investors and hedge funds have recently made changes to their positions in PCRX. Doma Perpetual Capital Management LLC raised its position in Pacira BioSciences by 49.7% during the third quarter. Doma Perpetual Capital Management LLC now owns 2,701,324 shares of the company's stock valued at $69,613,000 after purchasing an additional 897,255 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Pacira BioSciences by 0.5% during the third quarter. Dimensional Fund Advisors LP now owns 2,163,473 shares of the company's stock valued at $55,751,000 after purchasing an additional 11,831 shares in the last quarter. Balyasny Asset Management L.P. raised its position in Pacira BioSciences by 36.1% during the second quarter. Balyasny Asset Management L.P. now owns 2,130,733 shares of the company's stock valued at $50,925,000 after purchasing an additional 565,288 shares in the last quarter. American Century Companies Inc. raised its position in Pacira BioSciences by 16.6% during the third quarter. American Century Companies Inc. now owns 1,378,513 shares of the company's stock valued at $35,524,000 after purchasing an additional 196,000 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its position in Pacira BioSciences by 49.9% during the first quarter. Goldman Sachs Group Inc. now owns 1,104,796 shares of the company's stock valued at $27,454,000 after purchasing an additional 367,869 shares in the last quarter. Hedge funds and other institutional investors own 99.73% of the company's stock.
Wall Street Analyst Weigh In
PCRX has been the topic of a number of recent analyst reports. Wall Street Zen downgraded Pacira BioSciences from a "strong-buy" rating to a "buy" rating in a research report on Saturday, February 28th. Weiss Ratings upgraded Pacira BioSciences from a "sell (d)" rating to a "sell (d+)" rating in a research report on Wednesday, May 20th. Needham & Company LLC increased their price objective on Pacira BioSciences from $30.00 to $32.00 and gave the stock a "buy" rating in a research report on Friday, May 1st. Barclays lowered their price objective on Pacira BioSciences from $27.00 to $25.00 and set an "equal weight" rating on the stock in a research report on Thursday, March 26th. Finally, Zacks Research upgraded Pacira BioSciences from a "strong sell" rating to a "hold" rating in a research report on Tuesday, April 7th. Three research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $29.40.
View Our Latest Report on PCRX
About Pacira BioSciences
(
Get Free Report)
Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company's flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.
In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
